Beraprost Sodium

贝前列腺素钠

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameBeraprost Sodium
Drug Alias Name贝拉普罗钠伯罗普罗贝前列素钠贝前列素Beraprost-XR +[19] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstanoid receptor agonists
TargetsProstanoid receptor
Therapy Area/IndicationsPeripheral Vascular DiseasesArteriosclerosis ObliteransRenal Insufficiency, Chronic +[7] 
Global Approved IndicationsPeripheral Vascular DiseasesPulmonary Arterial Hypertension
Approved Indications in ChinaPeripheral Vascular DiseasesPulmonary Arterial Hypertension
Original Approved Country/TerritoryN/A
Original Approved Date1992/01/01
Country/TerritoryCzechiaBelgiumUnited States +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesToray Industries Inc
Inactive CompaniesAstellas Pharma IncKanae Co Ltd Tochigi PlantKyushu University +[5] 
Active IndicationsPeripheral Vascular DiseasesPulmonary Arterial Hypertension
Inactive IndicationsArteriosclerosis ObliteransRenal Insufficiency, ChronicRenal Insufficiency +[5] 

Other Information

ATC CodeB01AC19
Related LinksWikipediaDrugBankKEGG